While cell-specific differences in the regulation of FAK due to AMPK activation and insulin signalling are likely to exist, treatment strategies for metabolic disorders may be further validated through the study of the AMPK–FAK relationship in skeletal muscle, hepatic tissue or adipose tissue. The gene discussed is PTK2; the disease is metabolic disease.